The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.
Acute kidney injury (AKI) occurs in 7% to 40% of patients undergoing cardiac surgery, depending on the definition of AKI used. Even small increments in serum creatinine have been shown to be associated with increased mortality after cardiac surgery. However, there are no proven interventions to prevent AKI after cardiac surgery. Erythropoietin (EPO) has been shown to have tissue-protective effects in various experimental models. In this prospective placebo-controlled randomized trial, we evaluated the effectiveness of EPO in the prevention of AKI after coronary artery bypass grafting (CABG).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
71
300 IU/kg of EPO or saline intravenously before surgery
300 IU/kg of normal saline intravenously before surgery
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Number of Participants Who Had AKI (Acute Kidney Injury)
number of participants who had 50% increase in serum creatinine levels from baseline
Time frame: at any time within the first 5 days after surgery
Change in Estimated Glomerular Filtration Rate (eGFR)
estimated glomerular filtration rate (eGFR)as ml/min/1.73m2
Time frame: during the first 5 days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.